Phase I, Dose-Escalating Study of the Safety and Pharmacokinetics of Inhaled Dry-Powder Vancomycin (AeroVanc) in Volunteers and Patients with Cystic Fibrosis: a New Approach to Therapy for Methicillin-Resistant Staphylococcus aureus
Grant Waterer, John A.H. Lord, Thomas Hofmann, Taneli Jouhikainen
Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) has become a significant acute and chronic respiratory pathogen. While vancomycin is effective against MRSA, its relatively poor penetration into lung secretions and dose-limiting renal toxicity make it less effective in the respiratory setting. As inhaled administration of vancomycin would overcome these limitations, we developed a dry powder formulation suitable for inhalation (AeroVanc).
Topics & Concepts
MedicineVancomycinCystic fibrosisMethicillin-resistant Staphylococcus aureusPharmacokineticsStaphylococcus aureusInhalationAntibioticsToxicityPharmacodynamicsPharmacologyAnesthesiaMicrobiologyInternal medicineBacteriaBiologyGeneticsNosocomial Infections in ICUPneumonia and Respiratory InfectionsCystic Fibrosis Research Advances